Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Holding GMAB?
Track your performance easily
GMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$20.34 - $32.88
Previous Close$20.47
Volume706.28K
Average Volume (3M)1.02M
Market Cap
$13.52B
Enterprise Value$9.50B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)19.6
Beta0.64
Next Earnings
Feb 12, 2025EPS Estimate
$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.04
Shares Outstanding660,745,350
10 Day Avg. Volume1,579,563
30 Day Avg. Volume1,024,474
Standard Deviation0.10
R-Squared0.27
Alpha-0.00672
Financial Highlights & Ratios
Price to Book (P/B)0.43
Price to Sales (P/S)5.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$39.00Price Target Upside88.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Genmab News
PremiumCompany Announcements
Genmab Aligns Employee Incentives with Stock Units
PremiumCompany Announcements
Genmab Reports Strong Growth and Strategic Advances
PremiumCompany Announcements
Genmab’s Revenue Soars with Strategic Developments
PremiumCompany Announcements
Genmab Sees Strong DARZALEX Sales in Q3 2024
PremiumCompany Announcements
Baillie Gifford Acquires 4.99% Stake in Genmab A/SBulls Say, Bears Say
Bulls Say
Financial PerformanceGenmab reported revenue growth attributed to increased royalties from Darzalex, Kesimpta, and increased sales from Epkinly, demonstrating strong performance and growth.
Pipeline And InnovationGenmab's expertise in antibody design and progress with agents like EPKINLY demonstrate its innovative capabilities, with a broad pipeline offering potential for numerous clinical data catalysts.
Product ExpansionFor Epkinly, management is actively working to build off a successful commercial launch and expand into new indications with multiple ongoing clinical trials, showcasing a proactive approach to growth.
Bears Say
Competitive And Market ChallengesConcerns exist around acasunlimab due to equivocal initial Phase 2 data and the competitive NSCLC market, especially after BioNTech opted not to participate further in its development.
Patent And Sales RisksThe stock has been weak due to a lack of meaningful catalysts and increasing concern about how Genmab will overcome the Darzalex patent cliff in 2030.
Program Termination And Development IssuesGMAB announced the termination of three early-stage programs and the decision not to initiate a planned Phase III study for Tivdak.
---
Ownership Overview
―
Insiders
1.18% Mutual Funds
1.89% Other Institutional Investors
96.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $20.34 and its highest was $32.88 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 12, 2025 which is in 81 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 06, 2024. The company reported $0.287 earnings per share for the quarter, missing the consensus estimate of $0.308 by -$0.021.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is $0.35.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,768,300 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.287 in its last earnings report, missing expectations of $0.308. Following the earnings report the stock price went down -1.846%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Graham Capital Management, L.P.. It holds Genmab A/S’s shares valued at 978K.
---
Genmab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$39.00 (88.68% Upside)
$39.00 (88.68% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 17.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.96%
12-Months-Change
Fundamentals
Return on Equity
14.67%
Trailing 12-Months
Asset Growth
18.68%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q3 2024
0:00 / 0:00
---
GMAB Stock 12 Month Forecast
Average Price Target
$39.00
▲(88.68% Upside)
Technical Analysis
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-17.37%
assigned a buy rating 5 days ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -17.37% per trade.
---